Treatment

BLU-451 clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedPhase I and Phase II (Integrated)- First administration to humans
Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR exon20 Insertion Mutations
This study is testing a new drug, BLU-451, for people with advanced cancers that have a specific genetic change (EGFR exon20 insertion mutations). We want to find the safest dose and see how well it works to shrink tumours or stop them from growing.
For: Advanced cancers with EGFR Exon20 insertions mutations
Spain